Carlo Agrappi
Overview
Explore the profile of Carlo Agrappi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
110
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Paschale M, Manco M, Cianflone A, Belvisi L, Cagnin D, Cerulli T, et al.
J Clin Virol
. 2018 Sep;
108:77-82.
PMID: 30266004
Background: Simultaneous detection of HIV 1 and 2 antibodies and HIV-1 p-24 antigen in the 4th generation tests is particularly effective for the identification of early acute HIV infections while...
2.
Principe L, Piazza A, Mauri C, Anesi A, Bracco S, Brigante G, et al.
Infect Drug Resist
. 2018 Mar;
11:377-385.
PMID: 29563818
Background: The emergence of the plasmid-mediated colistin resistance mechanism in has raised concern among public health experts as colistin is a last-line antimicrobial resort. The primary aim of the study...
3.
De Paschale M, Manco M, Arpino O, Ricucci V, Paganini A, Belvisi L, et al.
J Med Virol
. 2017 Apr;
89(10):1817-1822.
PMID: 28401710
Some international guidelines recommend evaluating the need to confirm positive anti-hepatitis C virus (HCV) antibody screening results by means of a more specific antibody or molecular biology test on the...
4.
De Paschale M, Manco M, Belvisi L, Cagnin D, Cerulli T, Paganini A, et al.
J Med Virol
. 2016 Jul;
89(3):489-496.
PMID: 27467710
The aim of this study was to compare the data obtained using the new LIAISON® XL chemiluminescence system to search for HBsAg, anti-HCV, and anti-HIV1-2/p24 Ag with those obtained using...
5.
De Paschale M, Manco M, Paganini A, Agrappi C, Mirri P, Cucchi G, et al.
Infect Dis Rep
. 2014 Jan;
4(1):e17.
PMID: 24470924
Various countries have implemented anti-rubella vaccination campaigns with the main aim of preventing congenital infection. In 2003, Italy joined the European WHO programme for the elimination of congenital rubella and...
6.
De Paschale M, Manco M, Belvisi L, Brando B, Latella S, Agrappi C, et al.
Blood Transfus
. 2012 Jun;
10(3):344-50.
PMID: 22682333
Background: The implementation of mass vaccinations against hepatitis B virus (HBV) has significantly reduced the prevalence of HBsAg-positive subjects. At the same time, the prevalence of the other markers of...
7.
De Paschale M, Agrappi C, Manco M, Cerulli T, Clerici P
J Clin Med Res
. 2011 Jun;
2(3):112-6.
PMID: 21629522
Background: Since 1998, Italian law requires serological screening for toxoplasmosis by the thirteenth week of pregnancy, and seronegative women should undergo further checks every 30 - 40 days until delivery...
8.
De Paschale M, Cagnin D, Cerulli T, Manco M, Agrappi C, Mirri P, et al.
Int J Microbiol
. 2010 Jul;
2010:695104.
PMID: 20652034
The presence of an "isolated viral capsid antigen (VCA) IgG" pattern in serum is not easy to interpret without the aid of further tests, such as specific immunoblotting or a...
9.
De Paschale M, Agrappi C, Manco M, Clerici P
J Virol Methods
. 2010 May;
168(1-2):121-5.
PMID: 20470827
A search for specific IgM antibodies was used for the detection of primary human cytomegalovirus (HCMV) infections, but the significance of the results is limited by the possible persistence of...
10.
De Paschale M, Agrappi C, Manco M, Paganini A, Clerici P
Infect Dis Obstet Gynecol
. 2009 Jul;
2009:206505.
PMID: 19639052
The fetal consequences of CMV infection make it one of the most serious infections contracted during pregnancy, but the scientific community is divided over the proposed implementation of preventive screening...